The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials
Open Access
- 30 September 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1423228
Abstract
Cardiovascular disease remains a major global health concern. The combination of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) has been shown to beneficially modify a range of cardiovascular risk factors. However, whether EPA and DHA have differential effects or potencies is currently unclear. A systematic review of randomized controlled trials (RCTs) that compared ≥2 g/day of near pure EPA and DHA was conducted. A total of 24 publications from nine unique RCTs were included. EPA and DHA both lower triglyceride levels, with DHA most likely having a slightly greater effect. Furthermore, both EPA and DHA increase high density lipoprotein (HDL) 2 cholesterol, which is cardioprotective, with the increase being greater with DHA. DHA appears to increase low density lipoprotein (LDL) cholesterol; however, DHA also increases LDL particle size, which would render LDL less atherogenic. DHA seems more effective than EPA in decreasing heart rate and blood pressure. Both EPA and DHA alter platelet function decreasing thrombogenicity, although they may have different actions on platelets. Both EPA and DHA decrease F2-isoprostanes, interpreted as a reduction in oxidative stress. They both decrease inflammatory gene expression and promote an anti-inflammatory oxylipin profile. These are all favorable effects with regard to cardiovascular disease risk. Effects of EPA and DHA on blood glucose are inconsistent. This review is constrained by the small number of high quality RCTs that directly compare EPA to DHA and report on outcomes other than blood lipids. There is a need for additional high-quality research to assess the independent effects of EPA and DHA on cardiovascular risk factors (e.g., inflammation, blood pressure, vascular function, platelet function) in larger and more diverse study populations.Keywords
This publication has 90 references indexed in Scilit:
- Should We “RESPECT EPA” More Now? EPA and DHA for Cardiovascular Risk ReductionCurrent Cardiology Reports, 2023
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular RiskJAMA, 2020
- Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular EventsJAMA, 2020
- ω-3 Polyunsaturated Fatty Acid Biomarkers and Coronary Heart DiseaseJAMA Internal Medicine, 2016
- Influence of omega-3 polyunsaturated fatty acid-supplementation on platelet aggregation in humans: A meta-analysis of randomized controlled trialsAtherosclerosis, 2013
- Effect of omega-3 fatty acids supplementation on endothelial function: A meta-analysis of randomized controlled trialsAtherosclerosis, 2012
- Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: A systematic reviewAtherosclerosis, 2006
- EPA, but not DHA, decreases mean platelet volume in normal subjectsLipids, 2002
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Effect of omega-3 fatty acids on the vascular response to angiotensin in normotensive menThe American Journal of Cardiology, 1992